Novel Biomarkers Identified for Incident Coronary Heart Disease
By LabMedica International staff writers Posted on 24 Dec 2014 |
Image: The Xevo G2 quadrupole time-of-flight mass spectrometer (Q-TOFMS) (Photo courtesy of Waters Corporation).
Metabolic profiling has identified circulating, novel lipid-derived molecules that are associated with future coronary heart disease events, which will enable early diagnosis of cardiovascular disease.
The use of used novel biochemical and bioinformatics to identify such biomarkers are not only important for risk stratification and treatment decisions, but can also improve understanding of cardiovascular disease pathophysiology to identify new drug targets.
A team of scientists from Karolinska Institutet (Stockholm, Sweden) and their colleagues at Uppsala University (Sweden) performed a mass spectrometry-based non-targeted metabolomics study for association with incident coronary heart disease (CHD) events in 1,028 individuals with 131 events; and a 10 year median follow-up with validation in 1,670 individuals with 282 events and a 3.9 year median follow-up.
Metabolomic profiling was performed on the Acquity ultra-performance liquid chromatography (UPLC) apparatus coupled to a Xevo G2 quadrupole time-of-flight mass spectrometer (Q-TOFMS) (Waters Corporation; Milford, USA) with an atmospheric electrospray interface operating in positive ion mode. Non-consecutive duplicate sample aliquots of 1 µL were injected onto an Acquity UPLC BEH C8 analytical column and mass analysis was performed in the full scan mode. Genotyping arrays used in each study were performed with Illumina Bead chip kits (Illumina; San Diego, CA, USA).
The metabolomic profiling identified two lipid metabolites, lysophosphatidylcholine and sphingomyelin that reduced the risk of developing coronary heart disease in three Swedish population studies. Another lipid metabolite, monoglyceride, was instead associated with increased risk of coronary heart disease. Lysophosphatidylcholines were negatively associated with body mass index, C-reactive protein and with less evidence of subclinical cardiovascular disease in an additional 970 participants.
The authors concluded that one of the strengths of this study was that all participants were profiled for both metabolites and genetic variants. Some of the metabolites showed strong association with genetic variants previously associated with coronary heart disease supporting a common underlying molecular mechanism. The results were replicated in studies with different follow-up time, blood partition, age and sex distribution, increasing the generalizability of the findings adding to the studies depth. The study was published on December 11, 2014, in the journal Public Library of Science Genetics.
Related Links:
Karolinska Institutet
Uppsala University
Waters Corporation
The use of used novel biochemical and bioinformatics to identify such biomarkers are not only important for risk stratification and treatment decisions, but can also improve understanding of cardiovascular disease pathophysiology to identify new drug targets.
A team of scientists from Karolinska Institutet (Stockholm, Sweden) and their colleagues at Uppsala University (Sweden) performed a mass spectrometry-based non-targeted metabolomics study for association with incident coronary heart disease (CHD) events in 1,028 individuals with 131 events; and a 10 year median follow-up with validation in 1,670 individuals with 282 events and a 3.9 year median follow-up.
Metabolomic profiling was performed on the Acquity ultra-performance liquid chromatography (UPLC) apparatus coupled to a Xevo G2 quadrupole time-of-flight mass spectrometer (Q-TOFMS) (Waters Corporation; Milford, USA) with an atmospheric electrospray interface operating in positive ion mode. Non-consecutive duplicate sample aliquots of 1 µL were injected onto an Acquity UPLC BEH C8 analytical column and mass analysis was performed in the full scan mode. Genotyping arrays used in each study were performed with Illumina Bead chip kits (Illumina; San Diego, CA, USA).
The metabolomic profiling identified two lipid metabolites, lysophosphatidylcholine and sphingomyelin that reduced the risk of developing coronary heart disease in three Swedish population studies. Another lipid metabolite, monoglyceride, was instead associated with increased risk of coronary heart disease. Lysophosphatidylcholines were negatively associated with body mass index, C-reactive protein and with less evidence of subclinical cardiovascular disease in an additional 970 participants.
The authors concluded that one of the strengths of this study was that all participants were profiled for both metabolites and genetic variants. Some of the metabolites showed strong association with genetic variants previously associated with coronary heart disease supporting a common underlying molecular mechanism. The results were replicated in studies with different follow-up time, blood partition, age and sex distribution, increasing the generalizability of the findings adding to the studies depth. The study was published on December 11, 2014, in the journal Public Library of Science Genetics.
Related Links:
Karolinska Institutet
Uppsala University
Waters Corporation
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans